Gilead Sciences shares rise 1.13% premarket after EU regulator backs lenacapavir for HIV prevention.

Gilead Sciences, Inc. rose 1.13% in premarket trading, driven by positive news regarding its HIV prevention drug. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion under accelerated review recommending lenacapavir, Gilead's injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final European Commission (EC) decision is expected later this year, and, if approved, lenacapavir will be marketed in the European Union (EU) under the trade name Yeytuo®.